Terms: = Head and neck cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889 AND Clinical Outcome
5 results:
1. Presumed Pathogenic Germ Line and Somatic Variants in African American Thyroid cancer.
Hurst ZA; Liyanarachchi S; Brock P; He H; Nabhan F; Veloski C; Toland AE; Ringel MD; Jhiang SM
Thyroid; 2024 Mar; 34(3):378-387. PubMed ID: 38062767
[No Abstract] [Full Text] [Related]
2. DNA repair biomarkers xpf and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.
Seiwert TY; Wang X; Heitmann J; Villegas-Bergazzi V; Sprott K; Finn S; O'Regan E; Farrow AD; Weichselbaum RR; Lingen MW; Cohen EE; Stenson K; Weaver DT; Vokes EE
PLoS One; 2014; 9(7):e102112. PubMed ID: 25019640
[TBL] [Abstract] [Full Text] [Related]
3. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract] [Full Text] [Related]
4. xpf expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
Vaezi A; Wang X; Buch S; Gooding W; Wang L; Seethala RR; Weaver DT; D'Andrea AD; Argiris A; Romkes M; Niedernhofer LJ; Grandis JR
Clin Cancer Res; 2011 Aug; 17(16):5513-22. PubMed ID: 21737503
[TBL] [Abstract] [Full Text] [Related]
5. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
[TBL] [Abstract] [Full Text] [Related]
